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Abstract: Most experimental models, including cell culture studies, have demon-
strated that over-expression of manganese superoxide dismutase (MnSOD) in cells 
bearing a carcinoma phenotype has anti-proliferative and tumour suppression chara-
cteristics. In contrast, when cervical carcinoma biopsies express MnSOD, there is a 
poor prognosis and resistance to radiation therapy. The results herein indicate that 
human cervical adenocarcinoma (HeLaS3) cells have increased MnSOD activity 
(up to 50 % of the total SOD activity) due to low expression of its repressor p53 
and a high level of oxidative stress arising from the cell culture conditions. High 
MnSOD activity may be related to HeLaS3 cell radioresistance, illustrated by a 
high IC50 of 3.4 Gy and by a relatively high level of cell viability after gamma 
irradiation. In contrast to MnSOD activity, cytosolic CuZnSOD activity decreased 
after ionising radiation. The catalase (Cat) activity was unchanged. IR also increa-
sed the nitric oxide synthase (NOS) activity. Such conditions lead to increased con-
centrations of the superoxide radical, hydrogen peroxide and NO·, which together 
may be responsible for the decreased expression of NF-B and unaltered Cat ac-
tivity. Therefore, the disturbed redox balance within HeLaS3 cells may be respon-
sible for the cytotoxicity observed at higher irradiation doses. It could be concluded 
that inhibition of the CuZnSOD activity may be an important target for the selective 
killing of radioresistant cancer cells. 
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INTRODUCTION 
Carcinoma of the uterine cervix is one of the most frequent malignancies in 
the human population with 500,000 newly diagnosed cases annually.1,2 It is usu-
ally treated by surgery in combination with subsequent ionising radiation (IR) 
therapy.35 Cervical carcinomas are characterised by the fact that approximately 
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half of the biopsies express manganese superoxide dismutase (MnSOD) and there 
is significant association between MnSOD expression, poor prognosis and resis-
tance to IR therapy.6 A cervical carcinoma cell culture model (HeLaS3 cells) 
constitutively possesses enhanced MnSOD activity, probably due to the inserted 
human papilloma virus E6 protein causing ubiquitination and degradation of p53.7 
In p53-deficient cervical carcinoma cells, resistance to irradiation correlates with 
an increased expression of MnSOD and this enzyme is negatively regulated at the 
transcriptional level by p53.8 Adaptation of these cells grown in culture may lead 
to up-regulation of the antioxidant defence enzymes.9 Thus, induced over-expres-
sion of MnSOD in HeLaS3 cells could further influence their response to a free 
radical challenge.10 
Elevated MnSOD activity represents a survival factor which is required for 
the maintenance of mitochondrial integrity in cells exposed to adverse conditi-
ons.11,12 It seems that there is an established molecular basis for the correlation of 
MnSOD expression in cervical carcinoma and resistance to IR therapy. As MnSOD 
is predominantly anti-apoptotic,13,14 MnSOD over-expression in tumours could 
offer a survival advantage to tumour cells, leading to their radioresistance due to 
their low apoptotic potential.15 High MnSOD activity leads to an increased am-
ount of hydrogen peroxide (H2O2) which could via NF-B activation and trans-
activation of the MnSOD gene build up a positive feed-forward loop.16 
NF-B is considered to be a primary oxidative stress-responsive transcript-
tion factor which plays a critical role in balancing pro- and anti-apoptotic activi-
ties.17,18 NF-B is sensitive to concentrations of ROS and can be activated by 
H2O2 in a cell type-specific manner.19 Increased activity of NF-B may promote 
the survival of mutated cells.20 In contrast, other studies have indicated that over-
expression of MnSOD is closely associated with tumour regression in vivo and 
loss of malignant phenotype in vitro.2123 The current prevailing theory of the tu-
mour-suppressing ability of MnSOD is that an imbalance in the redox state of the 
cell leads to an inhibition of cell proliferation. One explanation for these growth-
suppressive effects of MnSOD could be the resulting imbalance of the anti-
oxidant enzymes, which favours H2O2 accumulation.24 Possible mechanisms for 
the suggested tumour-suppressive consequences of MnSOD over-expression 
could be the modulation of specific oncogenes,25 up-regulation of protease 
inhibitors26 and inhibition of the transcription factors AP-1 and NF-B.27 
In the present study, alterations in the expression of NF-B and p53 and 
alterations in the activity of the major anti-oxidant enzymes MnSOD, CuZnSOD 
and catalase (Cat), and inducible nitric oxide (NO·) synthase activity (iNOS) in 
HeLaS3 cells exposed to IR were explored. The obtained data offer practical 
information concerning the therapeutic effects of IR when biopsies of human 
uterine cervical carcinoma express MnSOD. 
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EXPERIMENTAL 
Cell culture. The human uterine cervical adenocarcinoma cell line HeLaS3 was obtained from 
the American Type Culture Collection (Rockville, MD, USA). The cells were maintained in 95 % 
Ham’s F12 supplemented with 5 % heat-inactivated foetal calf serum, 100 IU ml-1 penicillin and 
streptomycin and 2 mM L-glutamine (all obtained from Sigma–Aldrich, Taufkirchen, Germany). The 
cells were grown as a monolayer in a humidified atmosphere of 95 % air and 5 % CO2 at 37 ºC. 
Asynchronous cultures were chosen for all the experiments because techniques for the synchroni-
sation of mammalian cell lines often lead to perturbation of cell cycle checkpoint mechanisms.28 
Cell irradiation. IR (2, 5 and 10 Gy of gamma-rays) was delivered during the exponential 
phase of cell growth using a 60Co source at a fixed dose rate of 20 Gy h-1. 
Cell viability. Cell growth and viability were determined using the Trypan Blue exclusion assay. 
Sample preparation and Western blot analyses. Trypsinised and washed cells were lysed us-
ing a buffer containing 10 mM Tris–HCl pH 7.4, 0.32 M sucrose, 5 mM MgCl2, 1 % Triton X-100 
and a protease inhibitor cocktail. The protein concentration in the cell lysates was determined by 
the Lowry method.29 Aliquots of lysates were mixed with denaturing buffer according to Laem-
mli,30 boiled (100 °C, 2 min), separated by SDS–polyacrylamide gel electrophoresis (60 μg of cell 
protein per gel lane) and transferred to nitrocellulose membranes. The membranes were blocked 
using 10 mM Tris buffer pH 7.4 supplemented with 150 mM NaCl, 1 % BSA and 0.1 % Tween-20. 
The membranes were separately incubated with rabbit anti-actin antibody (CSA-400), anti-mouse 
p53 antibody (KAM-CC002), both from Stressgen Biotechnologies, Victoria, BC, Canada, and rab-
bit anti-NF-B antibody (NF-B p65, C-20; SC-372, Santa Cruz Biotechnology, CA, USA). A se-
condary goat anti-rabbit IgG HRP conjugate (SAB-300) and an anti-mouse IgG HRP conjugate 
(SAB-100) (Stressgen Biotechnologies, Victoria, BC, Canada) were used for detection. The quanti-
fication of the specific antigen bands was performed using an UltroScan XL scanning laser densito-
meter and computer image processing. The level of detected proteins by Western blotting was ex-
pressed in arbitrary units (AU mg-1 of protein). 
Determination of enzyme activities. SOD activity in cell lysates was determined according to 
McCord and Fridovich as the percentage inhibition of superoxide ( 2O ) formation induced by the 
xanthine–xanthine oxidase system.31,32 The results are expressed as units mg-1 of total cellular pro-
tein. Cat activity was determined according to Claiborne.33 One unit of Cat activity is defined as 
the amount of enzyme that degrades 1 mol of H2O2 min-1 mg-1 of protein. 
Citrulline assay. The L-citrulline assay was used to measure the inducible NOS activity by a 
colorimetric assay of deproteinised samples, as previously described by Boyde et al.34 In parallel, 
L-citrulline was used as a standard and taken through the full assay procedure. All assay reagents 
were purchased from Sigma–Aldrich. 
Statistical analysis. The values are presented as mean ± standard deviation (SD) calculated 
from four individual experiments. Statistical significance was evaluated using the one-way analysis 
of variance and the Tukey post-hoc test; p < 0.05 was considered to be statistically significant. 
RESULTS AND DISSCUSION 
To investigate the effect of IR on cell viability and cell growth, HeLaS3 cells 
were irradiated with 2, 5 and 10 Gy, returned to normal culture conditions and 
then analysed 24, 48 and 72 h after irradiation. Cell growth inhibition, expressed 
as the cell viability index, Vi, was significantly reduced after IR treatment. This 
reduction was both time- and dose-dependent (Fig. 1B). The greatest effect of IR 
was observed after a dose of 10 Gy, which inhibited cell proliferation by 80 % (at 
72 h after irradiation, p < 0.001). The calculations indicated that the Vi was 18.13.0, 
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whilst the IR dose that decreased cell growth from 100 to 50 % (IC50) was 
3.40.2 Gy. This relatively high IC50 classifies HeLaS3 as a radioresistant cell li-
ne. This was confirmed with the high cell viability, which decreased to only 60 % 
after 10 Gy at 72 h post irradiation (Fig. 1A). The results indicated that IR-medi-
ated HeLaS3 tumour suppression occurred via a non-cytotoxic mechanism. 
Fig. 1. The time- and the dose-de-
pendence of cell viability (panel A) 
and cell viability index (panel B) of 
irradiated HeLaS3 cells. The results 
are presented as mean SD, n = 4. 
*p < 0.05, **p < 0.01 and ***p < 0.001, 
refer to differences between irradia-
ted samples vs. the respective control. 
In order to investigate the molecular basis of the anti-proliferative action of 
IR, the activity of the three anti-oxidant enzymes MnSOD, CuZnSOD and Cat, as 
well as of inducible NOS, was determined. It is known that selective elevation of 
MnSOD activity increases the resistance of both non-malignant and malignant 
cells to oxidants and oxidant-generating events such as IR3537 but may, under 
unbalanced conditions culminate in increased sensitivity. The high constitutive 
MnSOD expression in HeLaS3 cells, potentiated with mild oxidative stress under 
the cell culture conditions,9 may be related to their observed radioresistance, illu-
strated by their high IC50 and Vi. However, IR caused a further increase in the 
MnSOD activity (which is in agreement with observations of other authors)38 si-
multaneously with a decrease in the CuZnSOD activity (Fig. 2). Cytosolic CuZnSOD 
activity has generally not been found to be elevated in tumours. Furthermore, its ex-
pression is not dependent on the generation of reactive oxygen species (ROS).39 
This is in accordance with reports indicating that conditions generating 2O , such 
as IR, could induce the synthesis of MnSOD but not of CuZnSOD.40 The present 
observations concerning SOD activities were similar to those previously found in 
HTE epithelial cells and MCF-7 human breast adenocarcinoma cells.41 As the 
Cat activity remained unchanged (Table I), such a situation led to unbalanced 
conditions with a high pro-oxidative potential of endogenously formed H2O2. The 
high H2O2 concentration could also have been the reason for the inhibition of 
CuZnSOD activity, but not of MnSOD activity. Decreased CuZnSOD activity 
can contribute to decreased cell proliferation, as fibroblasts derived from CuZnSOD 
knockout animals proliferate more slowly (25 % less) than control cells, empha-
sising the importance of CuZnSOD activity in cell growth and survival.42 Inhibition 
of CuZnSOD activity may cause accumulation of endogenous 2O  and lead to free 
radical-mediated mitochondrial membrane damage, release of mitochondrial 
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cytochrome c and increase apoptosis of cancer cells.43 The present results also 
indicate that targeting CuZnSOD activity may be a promising approach to the se-
lective killing of cancer cells.43 Untoxified H2O2 may be related to cell cycle 
arrest in the S phase via Cip1 (p21) and cyclin D3 inhibition.44 IR induces a late 
S phase arrest in HeLaS3 cells. This latter observation was noted in a previous 
study45 as well as in an independent study.46 
Fig. 2. IR-induced changes in MnSOD and 
CuZnSOD activity in irradiated HeLaS3 
cells (analysed 72 h after irradiation). The 
results are presented as mean SD, n = 4. 
***p < 0.001 refers to differences between 
irradiated samples vs. the respective control. 
TABLE I. Antioxidant enzyme activity and expression level of transcription factors in irradiated 
HeLaS3 cells (analysed 72 h after irradiation). The results are presented as mean SD, n = 4. 
**p < 0.01 and ***p < 0.001 refer to differences between irradiated samples vs. the respective control 
 Catalase U mg-1 
L-Citrulline 
% of control 
NF-B 
AU mg-1 
p53 
AU mg-1 
Control 12.2  1.0 100.0  1.7 100.0  2.9 100.0  0.7 
2 Gy 12.8  1.8 107.5  2.5 89.8  4.6 99.5  1.2 
5 Gy 13.3  2.2 112.9  2.6** 82.1  6.9** 94.5  6.4 
10 Gy 13.9  1.6 115.2  0.8*** 75.1  4.7*** 94.1  3.7 
Key signalling networks which regulate the response to IR also involve the 
redox-sensitive transcriptional factors p53 and NF-B. In the current HeLaS3 
cell study, in contrast to some other cell lines,47 IR did not induce expression of 
p53.8 However, it led to a decreased expression of NF-B, by approximately 25 % 
(Table I). It is well established that NF-B may protect against a variety of apo-
ptotic signals. In addition, its decreased expression has been shown to enhance 
the sensitivity of tumours to apoptosis induced by IR. Furthermore, there is corre-
lation between increased NO· production after IR, NF-B inhibition by NO· and 
induction of apoptosis in several cell lines. These findings could explain the IR-me-
diated down-regulation of NF-B observed in this study. Increased activity of iNOS, 
measured by the citrulline assay (Table I), could be one of the reasons for the 
decreased NF-B expression. Another reason may be a mechanism involving 
over-expression of MnSOD. Such a signalling pathway linking MnSOD over-ex-
pression with down-regulation of NF-B has been described in MCF-7 cells.41 
CONCLUSIONS 
In conclusion, IR-induced cellular perturbations in HeLaS3 cells involve 
down-regulation of NF-B (p65) expression, increased activity of mitochondrial 
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MnSOD and unchanged Cat activity. Such a situation leads to an increase in the 
endogenous level of H2O2, which may be related to cell cycle arrest in the S phase 
via Cip1 (p21) and cyclin D3 inhibition.39 The present results also indicated that cy-
tosolic CuZnSOD activity decreased upon IR treatment, which could have been a 
consequence of a high endogenous concentration of H2O2, leading to decreased 
cell proliferation. Therefore, it is proposed that targeting CuZnSOD with an inhi-
bitory adjuvant drug may be a promising approach to the selective killing of can-
cer cells. 
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